Drug intelligence / Profile preview

tretinoin + clindamycin

Development stage
Approved
Lead developer
Valeant Pharmaceuticals
Modality
Small Molecules
Administration
Topical
01

Overview

Tretinoin + clindamycin is a topical fixed-dose combination small molecule gel containing clindamycin phosphate 1.2% and tretinoin 0.025% for the treatment of acne vulgaris in patients 12 years of age and older. It combines a lincosamide antibiotic with a retinoid to address complementary pathogenic drivers of acne: clindamycin suppresses bacterial protein synthesis in *Cutibacterium acnes* and contributes antibacterial and anti-inflammatory activity, while tretinoin activates retinoic acid receptors to normalize follicular keratinization and provide comedolytic and anticomedogenic effects. The product is applied once daily and is marketed under brands including Veltin and Ziana, with use centered on comedonal and mild-to-moderate inflammatory acne.

Brand names
VeltinZianaVelac
Other names
tretinoin + clindamycinclindamycin phosphate + tretinoinclindamycin phosphate and tretinoin gelclindamycin phosphate/tretinoin gelclindamycin phosphate 1.2% and tretinoin 0.025% gelclindamycin phosphate and tretinoin gel 1.2% / 0.025%
02

Targets

RARA (Retinoic acid receptor alpha)RXRB (Retinoid X receptor beta)PTC (50S ribosomal peptidyl transferase center)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)RXRG (RXRγ)RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on tretinoin + clindamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tretinoin + clindamycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call